Working… Menu

Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04927611
Recruitment Status : Recruiting
First Posted : June 16, 2021
Last Update Posted : September 24, 2021
D1 Medical Technology (Shanghai) Co., Ltd, China
Information provided by (Responsible Party):
Xian-Jun Yu, Fudan University

Brief Summary:
The aim of this study is to use single-cell sequencing technology to explore neuroendocrine neoplasm (NEN) molecular biological characteristics, tumor heterogeneity and cell subtypes. Besides. NEN models are constructed for basic research, including primary cell lines, organoids, and animal models.

Condition or disease Intervention/treatment
Neuroendocrine Neoplasm Procedure: Biopsy, open or laparoscopic surgery

Detailed Description:

Neuroendocrine neoplasm (NEN) generally refers to all tumors that originate from peptidergic neurons and neuroendocrine cells. It is a relatively rare tumor, ranging from indolent, slow-growing low-grade malignant tumors to obvious distant metastases. A series of malignant tumors. The most common place for neuroendocrine tumors is in the digestive system, and about two-thirds of neuroendocrine tumors occur in the gastrointestinal pancreas. However, with the change of people's living habits and the improvement of physical examination awareness, the incidence of neuroendocrine tumors increased from 1.09/100,000 in 1973 to 6.98/100,000 in 2012. The incidence has increased by 6 times compared with other tumors. , NENs increase more rapidly. The incidence of people over 65 years of age has increased by 8 times, and the incidence of people younger than 50 years of age has also increased by 3 times, and the incidence has been increasing year by year. It is worth noting that the average age of pancreatic neuroendocrine tumors is only 56.7-13.3 years old, showing a younger trend.

Because most neuroendocrine tumors lack specific manifestations, coupled with unique inert biological characteristics, clinicians often lack understanding, which can easily lead to misdiagnosis and treatment. Taking gastrointestinal pancreatic neuroendocrine tumors (GEP-NEN) as an example, due to the uneven diagnosis and treatment level, GEP-NEN patients may be diagnosed with a delay of up to 7 years. Because of this, as many as 40-95% of GEP-NEN patients have developed distant metastases at the time of diagnosis, and 65-95% of them have liver metastases. Liver metastasis is the most critical prognostic risk factor in GEP-NEN, and it has a decisive impact on the survival of patients. The 5-year survival rate of gastrointestinal neuroendocrine tumors with liver metastasis is 56%-83%, while the 5-year survival rate of pancreatic neuroendocrine tumors is only 48.8%, and the 10-year survival rate is only 30.2%. For limited-stage patients, even if radical surgical resection, up to 94% of cases will still have recurrence and metastasis within 5 years. For inoperable patients, although chemotherapy, targeted therapy, biological therapy and other methods can be used, the effect is still limited. Therefore, the systematic development of basic-clinical translational research on neuroendocrine tumors is very important and imminent.

Based on the above-mentioned problems, this project intends to conduct a systematic and in-depth study of neuroendocrine tumors: 1. Use single-cell sequencing technology to deeply study the molecular biological characteristics of NEN tumors, tumor heterogeneity and cell subtypes. 2. Construct NEN models, including primary cell lines, organoids, and mouse animal models. This study can establish a neuroendocrine tumor research system to find the molecular mechanism and potential intervention targets of NEN recurrence and metastasis, and provide clinicians with safe and effective treatment strategies, thereby improving the therapeutic effect of neuroendocrine tumors.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Single-cell Sequencing and Establishment of Cell Lines, Organoids, and Transplanted Tumor Models in Neuroendocrine Neoplasm
Actual Study Start Date : June 6, 2021
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy

Group/Cohort Intervention/treatment
Gastroenteropancreatic neuroendocrine neoplasms
Collect biopsy/surgical fresh tissue of gastroenteropancreatic neuroendocrine neoplasms.
Procedure: Biopsy, open or laparoscopic surgery
Collect NEN and PDAC biopsy or surgical fresh tissue to conduct single cell sequencing or model construction.

Pancreatic ductal adenocarcinoma
Collect biopsy/surgical fresh tissue of pancreatic ductal adenocarcinoma.
Procedure: Biopsy, open or laparoscopic surgery
Collect NEN and PDAC biopsy or surgical fresh tissue to conduct single cell sequencing or model construction.

Primary Outcome Measures :
  1. Bioinformatics analysis of single-cell sequencing results [ Time Frame: Half a year ]
    Analysis of NEN Molecular Biology Information Using Single Cell Sequencing Technology

  2. Model construction [ Time Frame: One year ]
    Collect fresh specimens of NEN to cultivate primary cell lines, construct organoids, and establish animal models of NEN

Secondary Outcome Measures :
  1. Exploration of NEN organoid [ Time Frame: One year ]
    To explore and optimize the medium scheme of NEN orgnoid and methods of histomorphological identification of type organs

  2. Tumor microenvironment [ Time Frame: One year ]
    The tumor microenvironment of NEN was analyzed

  3. Comparison of mechanism of NEN with PDAC [ Time Frame: Half a year ]
    Collect fresh specimens of pancreatic ductal adenocarcinoma (PDAC) for single-cell sequencing and organoid construction for comparison with NEN

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Collect specimens confirmed to be NEN or PDAC by surgery or biopsy histopathology for single-cell sequencing analysis and the construction of primary cells, organoids and animal models.

Inclusion Criteria:

  1. Between the ages of 18 and 80, with any gender;
  2. Physical fitness score ECOG 0~1 points;
  3. The diagnosis is considered as gastrointestinal pancreatic neuroendocrine tumor or pancreatic ductal adenocarcinoma;
  4. There is no obvious contraindication to surgery or biopsy;
  5. Uncompensated liver cirrhosis, acute and chronic hepatitis and other diseases;
  6. No history of other biliary tract related diseases;
  7. Volunteer to participate and sign the informed consent form. -

Exclusion Criteria:

  1. Patients with non-gastrointestinal pancreatic neuroendocrine tumors or pancreatic ductal adenocarcinoma confirmed pathologically;
  2. Suffer from other digestive system diseases, such as irritable bowel syndrome, inflammatory bowel disease;
  3. Those who have incomplete follow-up data or refuse to accept follow-up;
  4. Patients with other malignant tumors or hematological diseases; -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04927611

Layout table for location contacts
Contact: Xianjun Yu, MD, PhD +86-13801669875

Layout table for location information
China, Shanghai
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University Recruiting
Shanghai, Shanghai, China, 200032
Contact: Xianjun Yu, M.D., Ph.D.    +86-21-6417-5590   
Principal Investigator: Xianjun Yu, M.D., Ph.D.         
Sponsors and Collaborators
Fudan University
D1 Medical Technology (Shanghai) Co., Ltd, China
Layout table for investigator information
Principal Investigator: Xianjun Yu, MD, PhD Fudan University

Layout table for additonal information
Responsible Party: Xian-Jun Yu, President of Shanghai Pancreatic Cancer Institute, Fudan University Identifier: NCT04927611    
Other Study ID Numbers: CSPAC-NEN-1
First Posted: June 16, 2021    Key Record Dates
Last Update Posted: September 24, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Xian-Jun Yu, Fudan University:
Neuroendocrine Neoplasm
Single Cell Sequencing Technology
Primary Cell Culture
Patient-derived Tumor Xenograft
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue